Dominic Theuns.

Gust H. Bardy, M .D., Warren M. Smith, M.B., Margaret A. Hood, M.B., Ian G. Crozier, M.B., Iain C. Melton, M.B., Luc Jordaens, M.D., Ph.D., Dominic Theuns, Ph.D., Robert E. Recreation area, M.B., David J. Wright, M.D., Derek T. Connelly, M.D., Simon P. Fynn, M.D., Francis D. Murgatroyd, M.D., Johannes Sperzel, M.D.D., Stefan G. Spitzer, M.D., Andrey V. Ardashev, M.D., Ph.D., Amo Oduro, M.B., B.S., Lucas Boersma, M.D., Ph.D., Alexander H. Maass, M.D., Isabelle C. Van Gelder, M.D., Ph.D., Arthur A. Wilde, M.D., Ph.D., Pascal F. Van Dessel, M.D., Reinoud E. Knops, M.D., Craig S. Barr, M.B., Pierpaolo Lupo, M.D., Riccardo Cappato, M.D., and Andrew A.

Methods Patients From 20 April, 2005, to January 18, 2007, we recruited patients from 155 clinical centers in 32 countries .5 on the Kurtzke Expanded Disability Status Level .19 Sufferers were excluded from the analysis if several previous disease-modifying treatments had failed or if indeed they had received immunosuppressive therapy at any time before study access or cytokine-based therapy, intravenous immune globulin therapy, or plasmapheresis within 3 months before study entry. Patients were also excluded if they had abnormal results on hematologic testing within 28 days before study entry, had a disorder which could compromise immune function , or had acquired a relapse within 28 days before study entry.